No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
SGMO Sangamo Therapeutics
- 0.421
- +0.008+1.84%
Close Jun 18 16:00 ET
87.40MMarket Cap-225P/E (TTM)
0.468High0.400Low2.05MVolume0.420Open0.414Pre Close895.05KTurnover1.20%Turnover RatioLossP/E (Static)207.51MShares1.67052wk High1.54P/B72.00MFloat Cap0.29152wk Low--Dividend TTM170.94MShs Float51.375Historical High--Div YieldTTM16.51%Amplitude0.291Historical Low0.435Avg Price1Lot Size
Pre-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Nektar, Verastem Among Healthcare Additions in Russell Microcap; Assertio, Sangamo Removed
Russell 3000: Inovio, Ocugen Among Healthcare Additions; Assertio, Ginkgo Bioworks Among Deletions
Critical Insights From Sangamo Therapeutics Analyst Ratings: What You Need To Know
In the preceding three months, 4 analysts have released ratings for Sangamo Therapeutics (NASDAQ:SGMO), presenting a wide array of perspectives from bullish to bearish.The following table encapsulates
Express News | HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $5 Price Target
Sangamo Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 776.73% HC Wainwright & Co. → $5 Reiterates Buy → Buy 03/19/2024 776.73% HC Wainwright & Co. $3
US$3.50 - That's What Analysts Think Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Is Worth After These Results
Comments
The MINT platform, derived from Sangamo's extensive experience in protein-DNA interactions through its zinc finger technology.
Sangamo Therapeutics recently presented critical pre-clinical data on its innovative next-generation integrase technology, the Modular Integrase (MINT) platform, highlighting a significant advancement in the field of genome editing. The announcement came as part of their participation at the 27th Amer...
Sangamo Therapeutics recently presented critical pre-clinical data on its innovative next-generation integrase technology, the Modular Integrase (MINT) platform, highlighting a significant advancement in the field of genome editing. The announcement came as part of their participation at the 27th Amer...
$Sangamo Therapeutics(SGMO.US$ Sangamo Therapeutics To Present Neurology-Focused Pre-Clinical Data From Epigenetic Regulation, Capsid Delivery And Genome Engineering Platforms At 27th ASGCT Annual Meeting
1
1
2
The market anticipates continued poor revenue growth, potentially suppressing the P/S ratio. The company's forecast of declining revenue contributes to its low P/S. Without major changes, a drastic stock price increase seems unlikely.
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
